Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Sangamo presents update on phase I safety study of SB-728-T for HIV/AIDS

Nov. 19, 2009

Vicriviroc exhibits long-term safety in phase II HIV trials, phase III trials under way

Nov. 17, 2009

Promising preclinical and phase IIa data on S/GSK-1349572 disclosed

Nov. 16, 2009

Phase I/II data show VIR-576 to be safe and effective in HIV

Nov. 16, 2009

HIV infection therapeutic TBR-652 shows good PK and safety profile in healthy subjects

Nov. 13, 2009

Concert Pharmaceuticals begins phase Ib clinical trial of HIV therapeutic CTP-518

Nov. 10, 2009

AIDS Vaccine meeting snapshots: Phase I and II trials of candidate vaccines

Nov. 9, 2009

FDA approves labeling update for Reyataz to include 96-week CASTLE data

Nov. 9, 2009

FDA advisory committee to review Theratechnologies' NDA for tesamorelin

Nov. 9, 2009

Clinical evaluation of HIV antigen lipopeptide vaccines disclosed at AIDS Vaccine 2009

Nov. 6, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...